ERASCA, INC. ERAS 深 滬
等待開盤 10-04 09:30:00 美东时间
2.395
+0.265
+12.44%
華盛通- 最 高2.645
- 今 開2.14
- 成交量 422.07万股
- 最 低 2.13
- 昨 收 2.13
- 總市值 6.80亿
- 52周最高 3.305
- 市盈率 靜 --
- 換手率 1.49%
- 52周最低 1.01
- 委 比 4.17%
- 總股本 2.84亿
- 歷史最高 24.47
- 量 比 2.04
- 振 幅 24.18%
- 歷史最低 1.01
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
Shares of Concorde International Group Ltd. (NASDAQ:CIGL) rose sharply in pre-m...
10-02 17:48
Taylor Swift Teams Up With AMC For Global 'Showgirl' Album Release Party In Theatres October 3-5, 2025
Fans can celebrate the release of Taylor Swift's 12th studio album, The Life of a Showgirl, with TAYLOR SWIFT | THE OFFICIAL RELEASE PARTY OF A SHOWGIRL on thousands of movie theatre screens in the United States,
09-20 00:22
Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-03 20:25
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Erasca, Inc. will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025. The company's management will present at 3:20 pm ET and discuss its precision oncology therapies targeting RAS/MAPK pathway-driven cancers. A live audio webcast and replay will be available via Erasca.com/events. Erasca is focused on discovering and developing novel cancer treatments in this field.
09-02 12:00
Morgan Stanley Downgrades Erasca to Equal-Weight, Lowers Price Target to $2
Morgan Stanley analyst Jeffrey Hung downgrades Erasca (NASDAQ:ERAS) from Overweight to Equal-Weight and lowers the price target from $4 to $2.
08-18 19:50
Erasca Q2 EPS $(0.12) Misses $(0.11) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 58.62 percent increase over losses of $(0.29) per share from the same
08-13 04:16
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
Erasca, Inc. announced updates on its RAS-targeting therapies, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), with Phase 1 monotherapy data expected in 2026. The company highlighted IND clearances for both candidates and robust financials, including $387 million in cash as of June 2025, supporting operations into H2 2028. Q2 2025 R&D expenses were $21.2 million, down from $33.0 million in Q2 2024, while G&A expenses fell t...
08-12 20:01
杜莎夫人蜡像馆揭幕史上最大规模的蜡像发布项目
杜莎夫人蜡像馆揭幕史上最大规模的蜡像发布项目，推出13尊全新泰勒·斯威夫特（Taylor Swift）蜡像，将于四大洲13个城市同步登场。这次多尊蜡像同步发布是...
07-24 10:39
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulle...
06-30 23:02
